Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 8;15(10):e46686.
doi: 10.7759/cureus.46686. eCollection 2023 Oct.

Oral Anticoagulation in Patients With Atrial High-Rate Episodes: Focus on Clinical Implications

Smaro Dimou  1   2 , Vasiliki C Mystakidi  3 , Sotirios Chiotis  2 , Stylianos Daios  1 , Charalambos Kalantzis  4 , Nikias Milaras  4 , Theodoros D Karamitsos  1 , Haralambos Karvounis  1 , Georgios Efthimiadis  1 , Stylianos Paraskevaidis  1
Affiliations

Oral Anticoagulation in Patients With Atrial High-Rate Episodes: Focus on Clinical Implications

Smaro Dimou et al. Cureus. .

Abstract

Background Although previous studies showed that atrial high-rate episodes (AHREs) are associated with a higher risk of developing incident atrial fibrillation (AF) and thromboembolic events, their clinical significance is still unclear. The purpose of this study was to define whether there is any clinical impact on the occurrence of ischemic and hemorrhagic events in patients with AHREs and initiation of oral anticoagulation (OAC). Methodology Patients with AHREs who had received cardiac implantable electronic devices (CIEDs, i.e., dual-chamber pacemaker [PM] or implantable cardioverter defibrillator [ICD]) were included in the study. OAC initiation was decided by the assistant doctor. Patients who received OACs comprised the OAC group, while patients who were not referred for OAC initiation were included in the control group. The primary endpoint was the time to the event of the occurrence of thromboembolic events (thromboembolic event-free survival). Results A total of 154 individuals (77 in each group) were enrolled in the study, with a mean age of 72.5 years. The mean follow-up period for the OAC group was 19.1 months and for the control group, 18.9 months (P = 0.9). Thromboembolic events were noticed only in seven patients. Six of them were in the control group, and only one in the OAC group (P = 0.05). Major bleeding events were noticed in five patients, one of whom was in the control group and the rest in the OAC group (P = 0.17). Conclusions OAC therapy in patients with AHREs was not associated with a significant difference in the risk of thromboembolic and bleeding events. Baseline patient characteristics and AHRE duration may be useful to intensify the monitoring and management of patients with AHREs. Bleeding events may be indicators of cancer in patients with AHREs receiving OACs.

Keywords: atrial fibrillation; atrial high-rate episodes; bleeding; oral anticoagulation; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Kaplan-Meier curve for thromboembolic event-free survival according to OAC status (primary endpoint).
OAC, oral anticoagulant
See this image and copyright information in PMC

References

    1. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) Gorenek B Chair, Bax J, Boriani G, et al. Europace. 2017;19:1556–1578. - PubMed
    1. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Hindricks G, Potpara T, Dagres N, et al. Eur Heart J. 2021;42:373–498. - PubMed
    1. Newly detected atrial fibrillation following dual chamber pacemaker implantation. Cheung JW, Keating RJ, Stein KM, et al. J Cardiovasc Electrophysiol. 2006;17:1323–1328. - PubMed
    1. Atrial high-rate episodes in patients with devices without a history of atrial fibrillation: a systematic review and meta-analysis. Doundoulakis I, Gavriilaki M, Tsiachris D, et al. Cardiovasc Drugs Ther. 2022;36:951–958. - PubMed
    1. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Circulation. 1994;89:224–227. - PubMed

LinkOut - more resources